PatiSIrfanWJameelA, et al.
Obesity and cancer: A Current overview of epidemiology, pathogenesis, outcomes, and management. Cancers (Basel)2023;
15: 485. doi:10.3390/cancers15020485
8.
KassahunWTMehdornMBabelJ.The impact of obesity on surgical outcomes in patients undergoing emergency laparotomy for high-risk abdominal emergencies. BMC Surg2022;
22: 15. doi:10.1186/s12893-022-01466-6
9.
CullinaneCFullardACroghanSM, et al.
Effect of obesity on perioperative outcomes following gastrointestinal surgery: meta-analysis. BJS Open2023;
7: zrad026. doi:10.1093/bjsopen/zrad026
10.
PeriKEisenbergM.Review on the update in obesity management: Epidemiology. BMJ Public Health2024;
2: e000247. doi:10.1136/bmjph-2023-000247
11.
HrubyAHuFB.The epidemiology of obesity: A big picture. Pharmacoeconomics2015;
33: 673–689. doi:10.1007/s40273-014-0243-x
12.
MachadoPPSteeleEMLevyRB, et al.
Ultra-processed food consumption and obesity in the Australian adult population. Nutr Diabetes2020;
10: 39. doi:10.1038/s41387-020-00141-0
13.
LaneMMGamageEDuS, et al.
Ultra-processed food exposure and adverse health outcomes: Umbrella review of epidemiological meta-analysesBMJ2024;
384: e077310. doi:10.1136/bmj-2023-077310
14.
SchauerPRKashyapSRWolskiK, et al.
Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med2012;
366: 1567–1576. doi:10.1056/NEJMoa1200225
15.
EllsLJReesKBrownT, et al.
Interventions for treating children and adolescents with overweight and obesity: An overview of Cochrane reviews. Int J Obes2018;
42: 1823–1833. doi:10.1038/s41366-018-0230-y
16.
Shariq UsmanMDaviesMHallME, et al.
The cardiovascular effects of novel weight loss therapies. Eur Heart J2023;
44: 5036–5048. doi:10.1093/eurheartj/ehad664
17.
AlfarisNWaldropSJohnsonV, et al.
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: A narrative review. eClinicalMedicine2024;
75: 102782. doi:10.1016/j.eclinm.2024.102782
18.
PhilippeJPowersAC.Observations on the discovery of glucagon-like peptide-1 action. JAMA 2025; 333(22): 1951–1952. doi:10.1001/jama.2025.5142.
19.
WildingJPHBatterhamRLCalannaS, et al; STEP 1 Study Group.
Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med2021;
384: 989–1002. doi:10.1056/NEJMoa2032183
20.
KosiborodMNAbildstrømSZBorlaugBA, et al; STEP-HFpEF Trial Committees and Investigators.
Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med2023;
389: 1069–1084. doi:10.1056/NEJMoa2306963
21.
KosiborodMNPetrieMCBorlaugBA, et al; STEP-HFpEF DM Trial Committees and Investigators.
Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med2024;
390: 1394–1407. doi:10.1056/NEJMoa2313917
22.
PackerMZileMRKramerCM, et al; SUMMIT Trial Study Group.
Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med2025;
392: 427–437. doi:10.1056/NEJMoa2410027
23.
LoombaRHartmanMLLawitzEJ, et al; SYNERGY-NASH Investigators.
Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med2024;
391: 299–310. doi:10.1056/NEJMoa2401943
24.
TangHDonahooWTDeKoskyST, et al.
GLP-1RA and SGLT2i medications for type 2 diabetes and Alzheimer disease and related dementias. JAMA Neurol. Epub ahead of print 7 April 2025. doi:10.1001/jamaneurol.2025.0353
25.
SeminerAMulihanoAO’BrienC, et al.
Cardioprotective glucose-lowering agents and dementia risk. A systematic review and meta-analysis. JAMA Neurol2025;
82(5): 450–460. doi:10.1001/jamaneurol.2025.0360
26.
WangLXuRKaelberDC, et al.
Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open2024;
7: e2421305. doi:10.1001/jamanetworkopen.2024.21305
27.
AshrufOSHundalJMushtaqA, et al.
Hematologic cancers among patients with type 2 diabetes prescribed GLP-1 receptor agonists. JAMA Netw Open2025;
8: e250802. doi:10.1001/jamanetworkopen.2025.0802
28.
KlausenMKThomsenMWortweinG, et al.
The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol2022;
179: 625–641. doi:10.1111/bph.15677
29.
LähteenvuoMTiihonenJSolismaaA, et al.
Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry2025;
82: 94–98. doi:10.1001/jamapsychiatry.2024.3599
30.
OstrominskiJWOrtega-MontielJTesfayeH, et al.
Trends in utilization of glucose- and weight-lowering medications after tirzepatide approval in the United States: A population-based cohort study. Ann Intern Med. Epub ahead of print 15 April 2025. doi:10.7326/ANNALS-24-02870
31.
HulstAHPlummerMPHollmannMW, et al.
Systematic review of incretin therapy during peri-operative and intensive care. Crit Care2018;
22: 299. doi:10.1186/s13054-018-2197-4
32.
JärvholmKJansonAHenfridssonP, et al.
Metabolic and bariatric surgery for adolescents with severe obesity: Benefits, risks, and specific considerations. Scand J Surg2025;
114: 95–106. doi:10.1177/14574969241297517.
33.
DruckerDJ.The GLP-1 journey: From discovery science to therapeutic impact. J Clin Invest2024;
134: e175634. doi:10.1172/JCI175634
34.
BeamWBHunter GuevaraLR.Are serious anesthesia risks of semaglutide and other GLP-1 agonists under-recognized? Case reports of retained solid gastric contents in patients undergoing anesthesia. APSF Newsletter2023;
38: 67,69–71.
35.
SilveiraSQda SilvaLMde Campos Vieira AbibA, et al.
Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy. J Clin Anesth2023;
87: 111091. doi:10.1016/j.jclinane.2023.111091
36.
SherwinMHamburgerJKatzD, et al.
Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: A prospective observational study in volunteers without obesity recently started on semaglutide. Can J Anaesth2023;
70: 1300–1306. doi:10.1007/s12630-023-02549-5
37.
PfeiferKJSelzerAMendezCE, et al.
Preoperative management of endocrine, hormonal, and urologic medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. Mayo Clin Proc2021;
96: 1655–1669. doi:10.1016/j.mayocp.2020.10.002
GarianiKPutzuA.Glucagon-like peptide-1 receptor agonists in the perioperative period: Implications for the anaesthesiologist. Eur J Anaesthesiol2024;
41: 245–246. doi:10.1097/EJA.0000000000001914
KindelTLWangAYWadhwaA, et al; Representing the American Gastroenterological Association, American Society for Metabolic and Bariatric Surgery, American Society of Anesthesiologists, International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons.
Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surg Endosc2025;
39: 180–183. doi:10.1007/s00464-024-11263-2
44.
EngelhardtTWebsterNR.Pulmonary aspiration of gastric contents in anaesthesia. Br J Anaesth1999;
83: 453e60. doi:10.1093/bja/83.3.453
Baig MU, Piazza A, Lahooti A, et al. Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric content and aspiration in patients undergoing gastrointestinal endoscopy: A systematic review and a metaanalysis. Gastrointest Endosc 2024. doi:10.1016/j.gie.2024.12.019
47.
ChenYZinkTChenY, et al.
Postoperative aspiration pneumonia among adults using GLP-1 receptor agonists. JAMA Netw Open2025;
8: e250081. doi:10.1001/jamanetworkopen.2025.0081
48.
El-BoghdadlyKWojcikiewicz T and Perlas A.
Perioperative point-of-care gastric ultrasound. BJA Educ2019;
19: 219–226. doi:10.1016/j.bjae.2019.03.003
49.
HashimMMIsmailMAEsmatAM, et al.Difficult tracheal intubation in bariatric surgery patients, a myth or reality?Br J Anaesth2016;
116: 557–558. doi:10.1093/bja/aew039
